Treace Medical Concepts, Inc. (TMCI)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Wall Street Analysts See a 41.11% Upside in Treace Medical Concepts (TMCI): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Treace Medical Concepts (TMCI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Treace Medical Concepts, Inc. (TMCI) Q1 2025 Earnings Call Transcript
Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Lily Lozada - JPMorgan Felipe Lamar - Truist Jayna Francis - UBS Operator Good day and thank you for standing by. Welcome to the Treace Medical Concepts First Quarter 2025 Earnings Conference Call.
Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.30 per share a year ago.
Treace Medical Concepts, Inc. (TMCI) Q4 2024 Earnings Call Transcript
Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Vivian Cervantes - Investor Relations, Gilmartin Group John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Lily Lozada - JPMorgan Kallum Titchmarsh - Morgan Stanley Richard Newitter - Truist Securities Danielle Antalffy - UBS Ben Haynor - Lake Street Capital Markets Operator Welcome to the Treace Medical Concepts Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.10 per share a year ago.
An Investigation Has Commenced on Behalf of Treace Medical Concepts, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your TMCI Losses
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc.") (NASDAQ:TMCI) concerning possible violations of federal securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Treace Medical Concepts Inc Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Treace Medical Concepts, Inc. (TMCI) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc.") (NASDAQ:TMCI) concerning possible violations of federal securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Treace Medical Concepts, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
An Investigation Has Commenced on Behalf of Treace Medical Concepts, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your TMCI Losses
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc.") (NASDAQ:TMCI) concerning possible violations of federal securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Treace Medical Concepts Inc Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Lost Money on Treace Medical Concepts, Inc.(TMCI)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc.") (NASDAQ:TMCI) concerning possible violations of federal securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
